Global Peptide API CDMO Services Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Peptide API CDMO Services market size was valued at US$ 4080 million in 2025 and is forecast to a readjusted size of US$ 13920 million by 2032 with a CAGR of 18.7% during review period.
Peptide API CDMO Services refer to outsourced development and manufacturing services for therapeutic peptide active pharmaceutical ingredients, typically covering discovery-scale synthesis, process development, analytical development and validation, quality studies, regulatory support, GMP scale-up, and commercial supply, with peptide drug substance rather than finished dosage forms as the primary deliverable. The upstream supply base mainly includes protected and specialty amino acids, solid-phase synthesis resins, coupling reagents, cleavage and deprotection reagents, organic solvents such as acetonitrile, purification media, analytical consumables, and GMP packaging materials, while the main downstream customers are innovative pharmaceutical companies, biotech firms, peptide generic and specialty drug developers, and manufacturers that formulate the API into injectable or other finished products. The 2025 gross margin of this segment showed wide dispersion because profitability depends heavily on development-stage mix, capacity utilization, commercial-scale execution, and process complexity; a realistic industry range is about 20%-55%, with development-heavy and high-value projects generally delivering higher margins, while platforms in large-scale ramp-up or major capacity expansion phases tend to report lower margins.
The peptide API CDMO services market is shifting from an outsourcing model centered mainly on early-stage development programs to a more integrated model covering process development, regulatory support, clinical supply, and commercial manufacturing. As peptide therapeutics continue to attract strong industry attention in metabolic disease, cardiovascular disease, oncology, and other chronic indications, customer requirements are becoming much more demanding. Buyers are no longer focused only on basic synthesis capability, but are placing greater emphasis on scale-up execution, impurity control, quality system maturity, and reliable long-term supply. For service providers, the ability to support a smooth transition from development to commercialization has become a critical part of market competitiveness.
On the supply side, the industry is moving toward greater scale, stronger platform integration, and more refined manufacturing capabilities. Peptide API production requires high standards in route design, purification efficiency, yield control, solvent management, and batch consistency, which is why leading companies continue to invest in production facilities, analytical capabilities, green process technologies, and quality management systems. At the same time, customers are paying closer attention to multi-region supply assurance and efficient technology transfer, making service providers with multi-site operations, solid validation experience, and strong engineering capability better positioned to win late-stage programs and long-term partnerships.
On the demand side, the market is being driven primarily by the continued expansion of peptide drug pipelines, the ramp-up of marketed products, and the increasing willingness of pharmaceutical and biotech companies to outsource complex molecule development and manufacturing. More innovators are relying on specialized CDMO platforms to reduce capital intensity, shorten development timelines, and lower execution risk during scale-up. In parallel, the growing use of long-acting designs, molecular modifications, and higher-complexity peptide structures is raising customer expectations for process expertise, regulatory support, and commercial manufacturing experience, creating broader opportunities for providers with strong end-to-end capabilities.
At the same time, the market still faces meaningful constraints and operational challenges. Peptide API manufacturing depends heavily on key raw materials, resins, coupling systems, purification media, and highly disciplined quality infrastructure, so supply chain volatility and cost pressure can easily affect manufacturing performance. In addition, although capacity expansion remains active across the industry, new facilities must still go through validation, ramp-up, customer qualification, and commercial transition before their value can be fully realized. Companies that fall short in process robustness, environmental and safety compliance, global regulatory readiness, or operational efficiency may struggle to convert new capacity into sustainable growth. In the future, competition will be determined not simply by scale, but by how well companies balance technical depth, project execution, quality assurance, delivery resilience, and cost control.
This report is a detailed and comprehensive analysis for global Peptide API CDMO Services market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Peptide API CDMO Services market size and forecasts, in consumption value ($ Million), 2021-2032
Global Peptide API CDMO Services market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Peptide API CDMO Services market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Peptide API CDMO Services market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Peptide API CDMO Services market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Peptide API CDMO Services refer to outsourced development and manufacturing services for therapeutic peptide active pharmaceutical ingredients, typically covering discovery-scale synthesis, process development, analytical development and validation, quality studies, regulatory support, GMP scale-up, and commercial supply, with peptide drug substance rather than finished dosage forms as the primary deliverable. The upstream supply base mainly includes protected and specialty amino acids, solid-phase synthesis resins, coupling reagents, cleavage and deprotection reagents, organic solvents such as acetonitrile, purification media, analytical consumables, and GMP packaging materials, while the main downstream customers are innovative pharmaceutical companies, biotech firms, peptide generic and specialty drug developers, and manufacturers that formulate the API into injectable or other finished products. The 2025 gross margin of this segment showed wide dispersion because profitability depends heavily on development-stage mix, capacity utilization, commercial-scale execution, and process complexity; a realistic industry range is about 20%-55%, with development-heavy and high-value projects generally delivering higher margins, while platforms in large-scale ramp-up or major capacity expansion phases tend to report lower margins.
The peptide API CDMO services market is shifting from an outsourcing model centered mainly on early-stage development programs to a more integrated model covering process development, regulatory support, clinical supply, and commercial manufacturing. As peptide therapeutics continue to attract strong industry attention in metabolic disease, cardiovascular disease, oncology, and other chronic indications, customer requirements are becoming much more demanding. Buyers are no longer focused only on basic synthesis capability, but are placing greater emphasis on scale-up execution, impurity control, quality system maturity, and reliable long-term supply. For service providers, the ability to support a smooth transition from development to commercialization has become a critical part of market competitiveness.
On the supply side, the industry is moving toward greater scale, stronger platform integration, and more refined manufacturing capabilities. Peptide API production requires high standards in route design, purification efficiency, yield control, solvent management, and batch consistency, which is why leading companies continue to invest in production facilities, analytical capabilities, green process technologies, and quality management systems. At the same time, customers are paying closer attention to multi-region supply assurance and efficient technology transfer, making service providers with multi-site operations, solid validation experience, and strong engineering capability better positioned to win late-stage programs and long-term partnerships.
On the demand side, the market is being driven primarily by the continued expansion of peptide drug pipelines, the ramp-up of marketed products, and the increasing willingness of pharmaceutical and biotech companies to outsource complex molecule development and manufacturing. More innovators are relying on specialized CDMO platforms to reduce capital intensity, shorten development timelines, and lower execution risk during scale-up. In parallel, the growing use of long-acting designs, molecular modifications, and higher-complexity peptide structures is raising customer expectations for process expertise, regulatory support, and commercial manufacturing experience, creating broader opportunities for providers with strong end-to-end capabilities.
At the same time, the market still faces meaningful constraints and operational challenges. Peptide API manufacturing depends heavily on key raw materials, resins, coupling systems, purification media, and highly disciplined quality infrastructure, so supply chain volatility and cost pressure can easily affect manufacturing performance. In addition, although capacity expansion remains active across the industry, new facilities must still go through validation, ramp-up, customer qualification, and commercial transition before their value can be fully realized. Companies that fall short in process robustness, environmental and safety compliance, global regulatory readiness, or operational efficiency may struggle to convert new capacity into sustainable growth. In the future, competition will be determined not simply by scale, but by how well companies balance technical depth, project execution, quality assurance, delivery resilience, and cost control.
This report is a detailed and comprehensive analysis for global Peptide API CDMO Services market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Peptide API CDMO Services market size and forecasts, in consumption value ($ Million), 2021-2032
Global Peptide API CDMO Services market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Peptide API CDMO Services market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Peptide API CDMO Services market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Peptide API CDMO Services
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Peptide API CDMO Services market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- GMP Services
- Non-GMP Services
- SPPS
- LPPS
- Hybrid Technology
- Small-Scale (mg?g)
- Medium-Scale (g?kg)
- Large-Scale (kg?t)
- Commercial
- Scientific Research
- Other
- PolyPeptide (CH)
- Bachem (CH)
- AmbioPharm (US)
- CordenPharma (CH)
- CPC Scientific (US)
- Piramal Pharma Solutions (IN)
- Almac Group (UK)
- Aspen API (ZA)
- Neuland Laboratories (IN)
- USV (IN)
- Aurigene Pharmaceutical Services (IN)
- PeptiStar (JP)
- BCN Peptides (ES)
- Creative Peptides (US)
- Space Peptides (CH)
- Cambrex (US)
- Nippon Shokubai (JP)
- ScinoPharm (TW)
- ChengDu ShengNuo Biotec (CN)
- WuXi TIDES (CN)
- Asymchem (CN)
- Medtide (CN)
- Jiuzhou Pharma (CN)
- Hybio Pharmaceutical (CN)
- JYMed Peptide (CN)
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
- Chapter 1, to describe Peptide API CDMO Services product scope, market overview, market estimation caveats and base year.
- Chapter 2, to profile the top players of Peptide API CDMO Services, with revenue, gross margin, and global market share of Peptide API CDMO Services from 2021 to 2026.
- Chapter 3, the Peptide API CDMO Services competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
- Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
- Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Peptide API CDMO Services market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
- Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
- Chapter 12, the key raw materials and key suppliers, and industry chain of Peptide API CDMO Services.
- Chapter 13, to describe Peptide API CDMO Services research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Peptide API CDMO Services by Type
1.3.1 Overview: Global Peptide API CDMO Services Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Peptide API CDMO Services Consumption Value Market Share by Type in 2025
1.3.3 GMP Services
1.3.4 Non-GMP Services
1.4 Classification of Peptide API CDMO Services by Synthesis Technology
1.4.1 Overview: Global Peptide API CDMO Services Market Size by Synthesis Technology: 2021 Versus 2025 Versus 2032
1.4.2 Global Peptide API CDMO Services Consumption Value Market Share by Synthesis Technology in 2025
1.4.3 SPPS
1.4.4 LPPS
1.4.5 Hybrid Technology
1.5 Classification of Peptide API CDMO Services by Capacity Tier
1.5.1 Overview: Global Peptide API CDMO Services Market Size by Capacity Tier: 2021 Versus 2025 Versus 2032
1.5.2 Global Peptide API CDMO Services Consumption Value Market Share by Capacity Tier in 2025
1.5.3 Small-Scale (mg?g)
1.5.4 Medium-Scale (g?kg)
1.5.5 Large-Scale (kg?t)
1.6 Global Peptide API CDMO Services Market by Application
1.6.1 Overview: Global Peptide API CDMO Services Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Commercial
1.6.3 Scientific Research
1.6.4 Other
1.7 Global Peptide API CDMO Services Market Size & Forecast
1.8 Global Peptide API CDMO Services Market Size and Forecast by Region
1.8.1 Global Peptide API CDMO Services Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Peptide API CDMO Services Market Size by Region, (2021-2032)
1.8.3 North America Peptide API CDMO Services Market Size and Prospect (2021-2032)
1.8.4 Europe Peptide API CDMO Services Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Peptide API CDMO Services Market Size and Prospect (2021-2032)
1.8.6 South America Peptide API CDMO Services Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Peptide API CDMO Services Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 PolyPeptide (CH)
2.1.1 PolyPeptide (CH) Details
2.1.2 PolyPeptide (CH) Major Business
2.1.3 PolyPeptide (CH) Peptide API CDMO Services Product and Solutions
2.1.4 PolyPeptide (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 PolyPeptide (CH) Recent Developments and Future Plans
2.2 Bachem (CH)
2.2.1 Bachem (CH) Details
2.2.2 Bachem (CH) Major Business
2.2.3 Bachem (CH) Peptide API CDMO Services Product and Solutions
2.2.4 Bachem (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Bachem (CH) Recent Developments and Future Plans
2.3 AmbioPharm (US)
2.3.1 AmbioPharm (US) Details
2.3.2 AmbioPharm (US) Major Business
2.3.3 AmbioPharm (US) Peptide API CDMO Services Product and Solutions
2.3.4 AmbioPharm (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 AmbioPharm (US) Recent Developments and Future Plans
2.4 CordenPharma (CH)
2.4.1 CordenPharma (CH) Details
2.4.2 CordenPharma (CH) Major Business
2.4.3 CordenPharma (CH) Peptide API CDMO Services Product and Solutions
2.4.4 CordenPharma (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 CordenPharma (CH) Recent Developments and Future Plans
2.5 CPC Scientific (US)
2.5.1 CPC Scientific (US) Details
2.5.2 CPC Scientific (US) Major Business
2.5.3 CPC Scientific (US) Peptide API CDMO Services Product and Solutions
2.5.4 CPC Scientific (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 CPC Scientific (US) Recent Developments and Future Plans
2.6 Piramal Pharma Solutions (IN)
2.6.1 Piramal Pharma Solutions (IN) Details
2.6.2 Piramal Pharma Solutions (IN) Major Business
2.6.3 Piramal Pharma Solutions (IN) Peptide API CDMO Services Product and Solutions
2.6.4 Piramal Pharma Solutions (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Piramal Pharma Solutions (IN) Recent Developments and Future Plans
2.7 Almac Group (UK)
2.7.1 Almac Group (UK) Details
2.7.2 Almac Group (UK) Major Business
2.7.3 Almac Group (UK) Peptide API CDMO Services Product and Solutions
2.7.4 Almac Group (UK) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Almac Group (UK) Recent Developments and Future Plans
2.8 Aspen API (ZA)
2.8.1 Aspen API (ZA) Details
2.8.2 Aspen API (ZA) Major Business
2.8.3 Aspen API (ZA) Peptide API CDMO Services Product and Solutions
2.8.4 Aspen API (ZA) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Aspen API (ZA) Recent Developments and Future Plans
2.9 Neuland Laboratories (IN)
2.9.1 Neuland Laboratories (IN) Details
2.9.2 Neuland Laboratories (IN) Major Business
2.9.3 Neuland Laboratories (IN) Peptide API CDMO Services Product and Solutions
2.9.4 Neuland Laboratories (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Neuland Laboratories (IN) Recent Developments and Future Plans
2.10 USV (IN)
2.10.1 USV (IN) Details
2.10.2 USV (IN) Major Business
2.10.3 USV (IN) Peptide API CDMO Services Product and Solutions
2.10.4 USV (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 USV (IN) Recent Developments and Future Plans
2.11 Aurigene Pharmaceutical Services (IN)
2.11.1 Aurigene Pharmaceutical Services (IN) Details
2.11.2 Aurigene Pharmaceutical Services (IN) Major Business
2.11.3 Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Product and Solutions
2.11.4 Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Aurigene Pharmaceutical Services (IN) Recent Developments and Future Plans
2.12 PeptiStar (JP)
2.12.1 PeptiStar (JP) Details
2.12.2 PeptiStar (JP) Major Business
2.12.3 PeptiStar (JP) Peptide API CDMO Services Product and Solutions
2.12.4 PeptiStar (JP) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 PeptiStar (JP) Recent Developments and Future Plans
2.13 BCN Peptides (ES)
2.13.1 BCN Peptides (ES) Details
2.13.2 BCN Peptides (ES) Major Business
2.13.3 BCN Peptides (ES) Peptide API CDMO Services Product and Solutions
2.13.4 BCN Peptides (ES) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 BCN Peptides (ES) Recent Developments and Future Plans
2.14 Creative Peptides (US)
2.14.1 Creative Peptides (US) Details
2.14.2 Creative Peptides (US) Major Business
2.14.3 Creative Peptides (US) Peptide API CDMO Services Product and Solutions
2.14.4 Creative Peptides (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Creative Peptides (US) Recent Developments and Future Plans
2.15 Space Peptides (CH)
2.15.1 Space Peptides (CH) Details
2.15.2 Space Peptides (CH) Major Business
2.15.3 Space Peptides (CH) Peptide API CDMO Services Product and Solutions
2.15.4 Space Peptides (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Space Peptides (CH) Recent Developments and Future Plans
2.16 Cambrex (US)
2.16.1 Cambrex (US) Details
2.16.2 Cambrex (US) Major Business
2.16.3 Cambrex (US) Peptide API CDMO Services Product and Solutions
2.16.4 Cambrex (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Cambrex (US) Recent Developments and Future Plans
2.17 Nippon Shokubai (JP)
2.17.1 Nippon Shokubai (JP) Details
2.17.2 Nippon Shokubai (JP) Major Business
2.17.3 Nippon Shokubai (JP) Peptide API CDMO Services Product and Solutions
2.17.4 Nippon Shokubai (JP) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Nippon Shokubai (JP) Recent Developments and Future Plans
2.18 ScinoPharm (TW)
2.18.1 ScinoPharm (TW) Details
2.18.2 ScinoPharm (TW) Major Business
2.18.3 ScinoPharm (TW) Peptide API CDMO Services Product and Solutions
2.18.4 ScinoPharm (TW) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 ScinoPharm (TW) Recent Developments and Future Plans
2.19 ChengDu ShengNuo Biotec (CN)
2.19.1 ChengDu ShengNuo Biotec (CN) Details
2.19.2 ChengDu ShengNuo Biotec (CN) Major Business
2.19.3 ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Product and Solutions
2.19.4 ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.19.5 ChengDu ShengNuo Biotec (CN) Recent Developments and Future Plans
2.20 WuXi TIDES (CN)
2.20.1 WuXi TIDES (CN) Details
2.20.2 WuXi TIDES (CN) Major Business
2.20.3 WuXi TIDES (CN) Peptide API CDMO Services Product and Solutions
2.20.4 WuXi TIDES (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.20.5 WuXi TIDES (CN) Recent Developments and Future Plans
2.21 Asymchem (CN)
2.21.1 Asymchem (CN) Details
2.21.2 Asymchem (CN) Major Business
2.21.3 Asymchem (CN) Peptide API CDMO Services Product and Solutions
2.21.4 Asymchem (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.21.5 Asymchem (CN) Recent Developments and Future Plans
2.22 Medtide (CN)
2.22.1 Medtide (CN) Details
2.22.2 Medtide (CN) Major Business
2.22.3 Medtide (CN) Peptide API CDMO Services Product and Solutions
2.22.4 Medtide (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.22.5 Medtide (CN) Recent Developments and Future Plans
2.23 Jiuzhou Pharma (CN)
2.23.1 Jiuzhou Pharma (CN) Details
2.23.2 Jiuzhou Pharma (CN) Major Business
2.23.3 Jiuzhou Pharma (CN) Peptide API CDMO Services Product and Solutions
2.23.4 Jiuzhou Pharma (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.23.5 Jiuzhou Pharma (CN) Recent Developments and Future Plans
2.24 Hybio Pharmaceutical (CN)
2.24.1 Hybio Pharmaceutical (CN) Details
2.24.2 Hybio Pharmaceutical (CN) Major Business
2.24.3 Hybio Pharmaceutical (CN) Peptide API CDMO Services Product and Solutions
2.24.4 Hybio Pharmaceutical (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.24.5 Hybio Pharmaceutical (CN) Recent Developments and Future Plans
2.25 JYMed Peptide (CN)
2.25.1 JYMed Peptide (CN) Details
2.25.2 JYMed Peptide (CN) Major Business
2.25.3 JYMed Peptide (CN) Peptide API CDMO Services Product and Solutions
2.25.4 JYMed Peptide (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.25.5 JYMed Peptide (CN) Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Peptide API CDMO Services Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Peptide API CDMO Services by Company Revenue
3.2.2 Top 3 Peptide API CDMO Services Players Market Share in 2025
3.2.3 Top 6 Peptide API CDMO Services Players Market Share in 2025
3.3 Peptide API CDMO Services Market: Overall Company Footprint Analysis
3.3.1 Peptide API CDMO Services Market: Region Footprint
3.3.2 Peptide API CDMO Services Market: Company Product Type Footprint
3.3.3 Peptide API CDMO Services Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Peptide API CDMO Services Consumption Value and Market Share by Type (2021-2026)
4.2 Global Peptide API CDMO Services Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Peptide API CDMO Services Consumption Value Market Share by Application (2021-2026)
5.2 Global Peptide API CDMO Services Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Peptide API CDMO Services Consumption Value by Type (2021-2032)
6.2 North America Peptide API CDMO Services Market Size by Application (2021-2032)
6.3 North America Peptide API CDMO Services Market Size by Country
6.3.1 North America Peptide API CDMO Services Consumption Value by Country (2021-2032)
6.3.2 United States Peptide API CDMO Services Market Size and Forecast (2021-2032)
6.3.3 Canada Peptide API CDMO Services Market Size and Forecast (2021-2032)
6.3.4 Mexico Peptide API CDMO Services Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Peptide API CDMO Services Consumption Value by Type (2021-2032)
7.2 Europe Peptide API CDMO Services Consumption Value by Application (2021-2032)
7.3 Europe Peptide API CDMO Services Market Size by Country
7.3.1 Europe Peptide API CDMO Services Consumption Value by Country (2021-2032)
7.3.2 Germany Peptide API CDMO Services Market Size and Forecast (2021-2032)
7.3.3 France Peptide API CDMO Services Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Peptide API CDMO Services Market Size and Forecast (2021-2032)
7.3.5 Russia Peptide API CDMO Services Market Size and Forecast (2021-2032)
7.3.6 Italy Peptide API CDMO Services Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Peptide API CDMO Services Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Peptide API CDMO Services Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Peptide API CDMO Services Market Size by Region
8.3.1 Asia-Pacific Peptide API CDMO Services Consumption Value by Region (2021-2032)
8.3.2 China Peptide API CDMO Services Market Size and Forecast (2021-2032)
8.3.3 Japan Peptide API CDMO Services Market Size and Forecast (2021-2032)
8.3.4 South Korea Peptide API CDMO Services Market Size and Forecast (2021-2032)
8.3.5 India Peptide API CDMO Services Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Peptide API CDMO Services Market Size and Forecast (2021-2032)
8.3.7 Australia Peptide API CDMO Services Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Peptide API CDMO Services Consumption Value by Type (2021-2032)
9.2 South America Peptide API CDMO Services Consumption Value by Application (2021-2032)
9.3 South America Peptide API CDMO Services Market Size by Country
9.3.1 South America Peptide API CDMO Services Consumption Value by Country (2021-2032)
9.3.2 Brazil Peptide API CDMO Services Market Size and Forecast (2021-2032)
9.3.3 Argentina Peptide API CDMO Services Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Peptide API CDMO Services Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Peptide API CDMO Services Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Peptide API CDMO Services Market Size by Country
10.3.1 Middle East & Africa Peptide API CDMO Services Consumption Value by Country (2021-2032)
10.3.2 Turkey Peptide API CDMO Services Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Peptide API CDMO Services Market Size and Forecast (2021-2032)
10.3.4 UAE Peptide API CDMO Services Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Peptide API CDMO Services Market Drivers
11.2 Peptide API CDMO Services Market Restraints
11.3 Peptide API CDMO Services Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Peptide API CDMO Services Industry Chain
12.2 Peptide API CDMO Services Upstream Analysis
12.3 Peptide API CDMO Services Midstream Analysis
12.4 Peptide API CDMO Services Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Peptide API CDMO Services by Type
1.3.1 Overview: Global Peptide API CDMO Services Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Peptide API CDMO Services Consumption Value Market Share by Type in 2025
1.3.3 GMP Services
1.3.4 Non-GMP Services
1.4 Classification of Peptide API CDMO Services by Synthesis Technology
1.4.1 Overview: Global Peptide API CDMO Services Market Size by Synthesis Technology: 2021 Versus 2025 Versus 2032
1.4.2 Global Peptide API CDMO Services Consumption Value Market Share by Synthesis Technology in 2025
1.4.3 SPPS
1.4.4 LPPS
1.4.5 Hybrid Technology
1.5 Classification of Peptide API CDMO Services by Capacity Tier
1.5.1 Overview: Global Peptide API CDMO Services Market Size by Capacity Tier: 2021 Versus 2025 Versus 2032
1.5.2 Global Peptide API CDMO Services Consumption Value Market Share by Capacity Tier in 2025
1.5.3 Small-Scale (mg?g)
1.5.4 Medium-Scale (g?kg)
1.5.5 Large-Scale (kg?t)
1.6 Global Peptide API CDMO Services Market by Application
1.6.1 Overview: Global Peptide API CDMO Services Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Commercial
1.6.3 Scientific Research
1.6.4 Other
1.7 Global Peptide API CDMO Services Market Size & Forecast
1.8 Global Peptide API CDMO Services Market Size and Forecast by Region
1.8.1 Global Peptide API CDMO Services Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Peptide API CDMO Services Market Size by Region, (2021-2032)
1.8.3 North America Peptide API CDMO Services Market Size and Prospect (2021-2032)
1.8.4 Europe Peptide API CDMO Services Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Peptide API CDMO Services Market Size and Prospect (2021-2032)
1.8.6 South America Peptide API CDMO Services Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Peptide API CDMO Services Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 PolyPeptide (CH)
2.1.1 PolyPeptide (CH) Details
2.1.2 PolyPeptide (CH) Major Business
2.1.3 PolyPeptide (CH) Peptide API CDMO Services Product and Solutions
2.1.4 PolyPeptide (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 PolyPeptide (CH) Recent Developments and Future Plans
2.2 Bachem (CH)
2.2.1 Bachem (CH) Details
2.2.2 Bachem (CH) Major Business
2.2.3 Bachem (CH) Peptide API CDMO Services Product and Solutions
2.2.4 Bachem (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Bachem (CH) Recent Developments and Future Plans
2.3 AmbioPharm (US)
2.3.1 AmbioPharm (US) Details
2.3.2 AmbioPharm (US) Major Business
2.3.3 AmbioPharm (US) Peptide API CDMO Services Product and Solutions
2.3.4 AmbioPharm (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 AmbioPharm (US) Recent Developments and Future Plans
2.4 CordenPharma (CH)
2.4.1 CordenPharma (CH) Details
2.4.2 CordenPharma (CH) Major Business
2.4.3 CordenPharma (CH) Peptide API CDMO Services Product and Solutions
2.4.4 CordenPharma (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 CordenPharma (CH) Recent Developments and Future Plans
2.5 CPC Scientific (US)
2.5.1 CPC Scientific (US) Details
2.5.2 CPC Scientific (US) Major Business
2.5.3 CPC Scientific (US) Peptide API CDMO Services Product and Solutions
2.5.4 CPC Scientific (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 CPC Scientific (US) Recent Developments and Future Plans
2.6 Piramal Pharma Solutions (IN)
2.6.1 Piramal Pharma Solutions (IN) Details
2.6.2 Piramal Pharma Solutions (IN) Major Business
2.6.3 Piramal Pharma Solutions (IN) Peptide API CDMO Services Product and Solutions
2.6.4 Piramal Pharma Solutions (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Piramal Pharma Solutions (IN) Recent Developments and Future Plans
2.7 Almac Group (UK)
2.7.1 Almac Group (UK) Details
2.7.2 Almac Group (UK) Major Business
2.7.3 Almac Group (UK) Peptide API CDMO Services Product and Solutions
2.7.4 Almac Group (UK) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Almac Group (UK) Recent Developments and Future Plans
2.8 Aspen API (ZA)
2.8.1 Aspen API (ZA) Details
2.8.2 Aspen API (ZA) Major Business
2.8.3 Aspen API (ZA) Peptide API CDMO Services Product and Solutions
2.8.4 Aspen API (ZA) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Aspen API (ZA) Recent Developments and Future Plans
2.9 Neuland Laboratories (IN)
2.9.1 Neuland Laboratories (IN) Details
2.9.2 Neuland Laboratories (IN) Major Business
2.9.3 Neuland Laboratories (IN) Peptide API CDMO Services Product and Solutions
2.9.4 Neuland Laboratories (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Neuland Laboratories (IN) Recent Developments and Future Plans
2.10 USV (IN)
2.10.1 USV (IN) Details
2.10.2 USV (IN) Major Business
2.10.3 USV (IN) Peptide API CDMO Services Product and Solutions
2.10.4 USV (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 USV (IN) Recent Developments and Future Plans
2.11 Aurigene Pharmaceutical Services (IN)
2.11.1 Aurigene Pharmaceutical Services (IN) Details
2.11.2 Aurigene Pharmaceutical Services (IN) Major Business
2.11.3 Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Product and Solutions
2.11.4 Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Aurigene Pharmaceutical Services (IN) Recent Developments and Future Plans
2.12 PeptiStar (JP)
2.12.1 PeptiStar (JP) Details
2.12.2 PeptiStar (JP) Major Business
2.12.3 PeptiStar (JP) Peptide API CDMO Services Product and Solutions
2.12.4 PeptiStar (JP) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 PeptiStar (JP) Recent Developments and Future Plans
2.13 BCN Peptides (ES)
2.13.1 BCN Peptides (ES) Details
2.13.2 BCN Peptides (ES) Major Business
2.13.3 BCN Peptides (ES) Peptide API CDMO Services Product and Solutions
2.13.4 BCN Peptides (ES) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 BCN Peptides (ES) Recent Developments and Future Plans
2.14 Creative Peptides (US)
2.14.1 Creative Peptides (US) Details
2.14.2 Creative Peptides (US) Major Business
2.14.3 Creative Peptides (US) Peptide API CDMO Services Product and Solutions
2.14.4 Creative Peptides (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Creative Peptides (US) Recent Developments and Future Plans
2.15 Space Peptides (CH)
2.15.1 Space Peptides (CH) Details
2.15.2 Space Peptides (CH) Major Business
2.15.3 Space Peptides (CH) Peptide API CDMO Services Product and Solutions
2.15.4 Space Peptides (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Space Peptides (CH) Recent Developments and Future Plans
2.16 Cambrex (US)
2.16.1 Cambrex (US) Details
2.16.2 Cambrex (US) Major Business
2.16.3 Cambrex (US) Peptide API CDMO Services Product and Solutions
2.16.4 Cambrex (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Cambrex (US) Recent Developments and Future Plans
2.17 Nippon Shokubai (JP)
2.17.1 Nippon Shokubai (JP) Details
2.17.2 Nippon Shokubai (JP) Major Business
2.17.3 Nippon Shokubai (JP) Peptide API CDMO Services Product and Solutions
2.17.4 Nippon Shokubai (JP) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Nippon Shokubai (JP) Recent Developments and Future Plans
2.18 ScinoPharm (TW)
2.18.1 ScinoPharm (TW) Details
2.18.2 ScinoPharm (TW) Major Business
2.18.3 ScinoPharm (TW) Peptide API CDMO Services Product and Solutions
2.18.4 ScinoPharm (TW) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 ScinoPharm (TW) Recent Developments and Future Plans
2.19 ChengDu ShengNuo Biotec (CN)
2.19.1 ChengDu ShengNuo Biotec (CN) Details
2.19.2 ChengDu ShengNuo Biotec (CN) Major Business
2.19.3 ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Product and Solutions
2.19.4 ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.19.5 ChengDu ShengNuo Biotec (CN) Recent Developments and Future Plans
2.20 WuXi TIDES (CN)
2.20.1 WuXi TIDES (CN) Details
2.20.2 WuXi TIDES (CN) Major Business
2.20.3 WuXi TIDES (CN) Peptide API CDMO Services Product and Solutions
2.20.4 WuXi TIDES (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.20.5 WuXi TIDES (CN) Recent Developments and Future Plans
2.21 Asymchem (CN)
2.21.1 Asymchem (CN) Details
2.21.2 Asymchem (CN) Major Business
2.21.3 Asymchem (CN) Peptide API CDMO Services Product and Solutions
2.21.4 Asymchem (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.21.5 Asymchem (CN) Recent Developments and Future Plans
2.22 Medtide (CN)
2.22.1 Medtide (CN) Details
2.22.2 Medtide (CN) Major Business
2.22.3 Medtide (CN) Peptide API CDMO Services Product and Solutions
2.22.4 Medtide (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.22.5 Medtide (CN) Recent Developments and Future Plans
2.23 Jiuzhou Pharma (CN)
2.23.1 Jiuzhou Pharma (CN) Details
2.23.2 Jiuzhou Pharma (CN) Major Business
2.23.3 Jiuzhou Pharma (CN) Peptide API CDMO Services Product and Solutions
2.23.4 Jiuzhou Pharma (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.23.5 Jiuzhou Pharma (CN) Recent Developments and Future Plans
2.24 Hybio Pharmaceutical (CN)
2.24.1 Hybio Pharmaceutical (CN) Details
2.24.2 Hybio Pharmaceutical (CN) Major Business
2.24.3 Hybio Pharmaceutical (CN) Peptide API CDMO Services Product and Solutions
2.24.4 Hybio Pharmaceutical (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.24.5 Hybio Pharmaceutical (CN) Recent Developments and Future Plans
2.25 JYMed Peptide (CN)
2.25.1 JYMed Peptide (CN) Details
2.25.2 JYMed Peptide (CN) Major Business
2.25.3 JYMed Peptide (CN) Peptide API CDMO Services Product and Solutions
2.25.4 JYMed Peptide (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
2.25.5 JYMed Peptide (CN) Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Peptide API CDMO Services Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Peptide API CDMO Services by Company Revenue
3.2.2 Top 3 Peptide API CDMO Services Players Market Share in 2025
3.2.3 Top 6 Peptide API CDMO Services Players Market Share in 2025
3.3 Peptide API CDMO Services Market: Overall Company Footprint Analysis
3.3.1 Peptide API CDMO Services Market: Region Footprint
3.3.2 Peptide API CDMO Services Market: Company Product Type Footprint
3.3.3 Peptide API CDMO Services Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Peptide API CDMO Services Consumption Value and Market Share by Type (2021-2026)
4.2 Global Peptide API CDMO Services Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Peptide API CDMO Services Consumption Value Market Share by Application (2021-2026)
5.2 Global Peptide API CDMO Services Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Peptide API CDMO Services Consumption Value by Type (2021-2032)
6.2 North America Peptide API CDMO Services Market Size by Application (2021-2032)
6.3 North America Peptide API CDMO Services Market Size by Country
6.3.1 North America Peptide API CDMO Services Consumption Value by Country (2021-2032)
6.3.2 United States Peptide API CDMO Services Market Size and Forecast (2021-2032)
6.3.3 Canada Peptide API CDMO Services Market Size and Forecast (2021-2032)
6.3.4 Mexico Peptide API CDMO Services Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Peptide API CDMO Services Consumption Value by Type (2021-2032)
7.2 Europe Peptide API CDMO Services Consumption Value by Application (2021-2032)
7.3 Europe Peptide API CDMO Services Market Size by Country
7.3.1 Europe Peptide API CDMO Services Consumption Value by Country (2021-2032)
7.3.2 Germany Peptide API CDMO Services Market Size and Forecast (2021-2032)
7.3.3 France Peptide API CDMO Services Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Peptide API CDMO Services Market Size and Forecast (2021-2032)
7.3.5 Russia Peptide API CDMO Services Market Size and Forecast (2021-2032)
7.3.6 Italy Peptide API CDMO Services Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Peptide API CDMO Services Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Peptide API CDMO Services Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Peptide API CDMO Services Market Size by Region
8.3.1 Asia-Pacific Peptide API CDMO Services Consumption Value by Region (2021-2032)
8.3.2 China Peptide API CDMO Services Market Size and Forecast (2021-2032)
8.3.3 Japan Peptide API CDMO Services Market Size and Forecast (2021-2032)
8.3.4 South Korea Peptide API CDMO Services Market Size and Forecast (2021-2032)
8.3.5 India Peptide API CDMO Services Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Peptide API CDMO Services Market Size and Forecast (2021-2032)
8.3.7 Australia Peptide API CDMO Services Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Peptide API CDMO Services Consumption Value by Type (2021-2032)
9.2 South America Peptide API CDMO Services Consumption Value by Application (2021-2032)
9.3 South America Peptide API CDMO Services Market Size by Country
9.3.1 South America Peptide API CDMO Services Consumption Value by Country (2021-2032)
9.3.2 Brazil Peptide API CDMO Services Market Size and Forecast (2021-2032)
9.3.3 Argentina Peptide API CDMO Services Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Peptide API CDMO Services Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Peptide API CDMO Services Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Peptide API CDMO Services Market Size by Country
10.3.1 Middle East & Africa Peptide API CDMO Services Consumption Value by Country (2021-2032)
10.3.2 Turkey Peptide API CDMO Services Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Peptide API CDMO Services Market Size and Forecast (2021-2032)
10.3.4 UAE Peptide API CDMO Services Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Peptide API CDMO Services Market Drivers
11.2 Peptide API CDMO Services Market Restraints
11.3 Peptide API CDMO Services Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Peptide API CDMO Services Industry Chain
12.2 Peptide API CDMO Services Upstream Analysis
12.3 Peptide API CDMO Services Midstream Analysis
12.4 Peptide API CDMO Services Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Peptide API CDMO Services Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Peptide API CDMO Services Consumption Value by Synthesis Technology, (USD Million), 2021 & 2025 & 2032
Table 3. Global Peptide API CDMO Services Consumption Value by Capacity Tier, (USD Million), 2021 & 2025 & 2032
Table 4. Global Peptide API CDMO Services Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Peptide API CDMO Services Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Peptide API CDMO Services Consumption Value by Region (2027-2032) & (USD Million)
Table 7. PolyPeptide (CH) Company Information, Head Office, and Major Competitors
Table 8. PolyPeptide (CH) Major Business
Table 9. PolyPeptide (CH) Peptide API CDMO Services Product and Solutions
Table 10. PolyPeptide (CH) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. PolyPeptide (CH) Recent Developments and Future Plans
Table 12. Bachem (CH) Company Information, Head Office, and Major Competitors
Table 13. Bachem (CH) Major Business
Table 14. Bachem (CH) Peptide API CDMO Services Product and Solutions
Table 15. Bachem (CH) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Bachem (CH) Recent Developments and Future Plans
Table 17. AmbioPharm (US) Company Information, Head Office, and Major Competitors
Table 18. AmbioPharm (US) Major Business
Table 19. AmbioPharm (US) Peptide API CDMO Services Product and Solutions
Table 20. AmbioPharm (US) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. CordenPharma (CH) Company Information, Head Office, and Major Competitors
Table 22. CordenPharma (CH) Major Business
Table 23. CordenPharma (CH) Peptide API CDMO Services Product and Solutions
Table 24. CordenPharma (CH) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. CordenPharma (CH) Recent Developments and Future Plans
Table 26. CPC Scientific (US) Company Information, Head Office, and Major Competitors
Table 27. CPC Scientific (US) Major Business
Table 28. CPC Scientific (US) Peptide API CDMO Services Product and Solutions
Table 29. CPC Scientific (US) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. CPC Scientific (US) Recent Developments and Future Plans
Table 31. Piramal Pharma Solutions (IN) Company Information, Head Office, and Major Competitors
Table 32. Piramal Pharma Solutions (IN) Major Business
Table 33. Piramal Pharma Solutions (IN) Peptide API CDMO Services Product and Solutions
Table 34. Piramal Pharma Solutions (IN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Piramal Pharma Solutions (IN) Recent Developments and Future Plans
Table 36. Almac Group (UK) Company Information, Head Office, and Major Competitors
Table 37. Almac Group (UK) Major Business
Table 38. Almac Group (UK) Peptide API CDMO Services Product and Solutions
Table 39. Almac Group (UK) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Almac Group (UK) Recent Developments and Future Plans
Table 41. Aspen API (ZA) Company Information, Head Office, and Major Competitors
Table 42. Aspen API (ZA) Major Business
Table 43. Aspen API (ZA) Peptide API CDMO Services Product and Solutions
Table 44. Aspen API (ZA) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Aspen API (ZA) Recent Developments and Future Plans
Table 46. Neuland Laboratories (IN) Company Information, Head Office, and Major Competitors
Table 47. Neuland Laboratories (IN) Major Business
Table 48. Neuland Laboratories (IN) Peptide API CDMO Services Product and Solutions
Table 49. Neuland Laboratories (IN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Neuland Laboratories (IN) Recent Developments and Future Plans
Table 51. USV (IN) Company Information, Head Office, and Major Competitors
Table 52. USV (IN) Major Business
Table 53. USV (IN) Peptide API CDMO Services Product and Solutions
Table 54. USV (IN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. USV (IN) Recent Developments and Future Plans
Table 56. Aurigene Pharmaceutical Services (IN) Company Information, Head Office, and Major Competitors
Table 57. Aurigene Pharmaceutical Services (IN) Major Business
Table 58. Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Product and Solutions
Table 59. Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Aurigene Pharmaceutical Services (IN) Recent Developments and Future Plans
Table 61. PeptiStar (JP) Company Information, Head Office, and Major Competitors
Table 62. PeptiStar (JP) Major Business
Table 63. PeptiStar (JP) Peptide API CDMO Services Product and Solutions
Table 64. PeptiStar (JP) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. PeptiStar (JP) Recent Developments and Future Plans
Table 66. BCN Peptides (ES) Company Information, Head Office, and Major Competitors
Table 67. BCN Peptides (ES) Major Business
Table 68. BCN Peptides (ES) Peptide API CDMO Services Product and Solutions
Table 69. BCN Peptides (ES) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. BCN Peptides (ES) Recent Developments and Future Plans
Table 71. Creative Peptides (US) Company Information, Head Office, and Major Competitors
Table 72. Creative Peptides (US) Major Business
Table 73. Creative Peptides (US) Peptide API CDMO Services Product and Solutions
Table 74. Creative Peptides (US) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. Creative Peptides (US) Recent Developments and Future Plans
Table 76. Space Peptides (CH) Company Information, Head Office, and Major Competitors
Table 77. Space Peptides (CH) Major Business
Table 78. Space Peptides (CH) Peptide API CDMO Services Product and Solutions
Table 79. Space Peptides (CH) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. Space Peptides (CH) Recent Developments and Future Plans
Table 81. Cambrex (US) Company Information, Head Office, and Major Competitors
Table 82. Cambrex (US) Major Business
Table 83. Cambrex (US) Peptide API CDMO Services Product and Solutions
Table 84. Cambrex (US) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Cambrex (US) Recent Developments and Future Plans
Table 86. Nippon Shokubai (JP) Company Information, Head Office, and Major Competitors
Table 87. Nippon Shokubai (JP) Major Business
Table 88. Nippon Shokubai (JP) Peptide API CDMO Services Product and Solutions
Table 89. Nippon Shokubai (JP) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 90. Nippon Shokubai (JP) Recent Developments and Future Plans
Table 91. ScinoPharm (TW) Company Information, Head Office, and Major Competitors
Table 92. ScinoPharm (TW) Major Business
Table 93. ScinoPharm (TW) Peptide API CDMO Services Product and Solutions
Table 94. ScinoPharm (TW) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 95. ScinoPharm (TW) Recent Developments and Future Plans
Table 96. ChengDu ShengNuo Biotec (CN) Company Information, Head Office, and Major Competitors
Table 97. ChengDu ShengNuo Biotec (CN) Major Business
Table 98. ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Product and Solutions
Table 99. ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 100. ChengDu ShengNuo Biotec (CN) Recent Developments and Future Plans
Table 101. WuXi TIDES (CN) Company Information, Head Office, and Major Competitors
Table 102. WuXi TIDES (CN) Major Business
Table 103. WuXi TIDES (CN) Peptide API CDMO Services Product and Solutions
Table 104. WuXi TIDES (CN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 105. WuXi TIDES (CN) Recent Developments and Future Plans
Table 106. Asymchem (CN) Company Information, Head Office, and Major Competitors
Table 107. Asymchem (CN) Major Business
Table 108. Asymchem (CN) Peptide API CDMO Services Product and Solutions
Table 109. Asymchem (CN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 110. Asymchem (CN) Recent Developments and Future Plans
Table 111. Medtide (CN) Company Information, Head Office, and Major Competitors
Table 112. Medtide (CN) Major Business
Table 113. Medtide (CN) Peptide API CDMO Services Product and Solutions
Table 114. Medtide (CN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Medtide (CN) Recent Developments and Future Plans
Table 116. Jiuzhou Pharma (CN) Company Information, Head Office, and Major Competitors
Table 117. Jiuzhou Pharma (CN) Major Business
Table 118. Jiuzhou Pharma (CN) Peptide API CDMO Services Product and Solutions
Table 119. Jiuzhou Pharma (CN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 120. Jiuzhou Pharma (CN) Recent Developments and Future Plans
Table 121. Hybio Pharmaceutical (CN) Company Information, Head Office, and Major Competitors
Table 122. Hybio Pharmaceutical (CN) Major Business
Table 123. Hybio Pharmaceutical (CN) Peptide API CDMO Services Product and Solutions
Table 124. Hybio Pharmaceutical (CN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 125. Hybio Pharmaceutical (CN) Recent Developments and Future Plans
Table 126. JYMed Peptide (CN) Company Information, Head Office, and Major Competitors
Table 127. JYMed Peptide (CN) Major Business
Table 128. JYMed Peptide (CN) Peptide API CDMO Services Product and Solutions
Table 129. JYMed Peptide (CN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 130. JYMed Peptide (CN) Recent Developments and Future Plans
Table 131. Global Peptide API CDMO Services Revenue (USD Million) by Players (2021-2026)
Table 132. Global Peptide API CDMO Services Revenue Share by Players (2021-2026)
Table 133. Breakdown of Peptide API CDMO Services by Company Type (Tier 1, Tier 2, and Tier 3)
Table 134. Market Position of Players in Peptide API CDMO Services, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 135. Head Office of Key Peptide API CDMO Services Players
Table 136. Peptide API CDMO Services Market: Company Product Type Footprint
Table 137. Peptide API CDMO Services Market: Company Product Application Footprint
Table 138. Peptide API CDMO Services New Market Entrants and Barriers to Market Entry
Table 139. Peptide API CDMO Services Mergers, Acquisition, Agreements, and Collaborations
Table 140. Global Peptide API CDMO Services Consumption Value (USD Million) by Type (2021-2026)
Table 141. Global Peptide API CDMO Services Consumption Value Share by Type (2021-2026)
Table 142. Global Peptide API CDMO Services Consumption Value Forecast by Type (2027-2032)
Table 143. Global Peptide API CDMO Services Consumption Value by Application (2021-2026)
Table 144. Global Peptide API CDMO Services Consumption Value Forecast by Application (2027-2032)
Table 145. North America Peptide API CDMO Services Consumption Value by Type (2021-2026) & (USD Million)
Table 146. North America Peptide API CDMO Services Consumption Value by Type (2027-2032) & (USD Million)
Table 147. North America Peptide API CDMO Services Consumption Value by Application (2021-2026) & (USD Million)
Table 148. North America Peptide API CDMO Services Consumption Value by Application (2027-2032) & (USD Million)
Table 149. North America Peptide API CDMO Services Consumption Value by Country (2021-2026) & (USD Million)
Table 150. North America Peptide API CDMO Services Consumption Value by Country (2027-2032) & (USD Million)
Table 151. Europe Peptide API CDMO Services Consumption Value by Type (2021-2026) & (USD Million)
Table 152. Europe Peptide API CDMO Services Consumption Value by Type (2027-2032) & (USD Million)
Table 153. Europe Peptide API CDMO Services Consumption Value by Application (2021-2026) & (USD Million)
Table 154. Europe Peptide API CDMO Services Consumption Value by Application (2027-2032) & (USD Million)
Table 155. Europe Peptide API CDMO Services Consumption Value by Country (2021-2026) & (USD Million)
Table 156. Europe Peptide API CDMO Services Consumption Value by Country (2027-2032) & (USD Million)
Table 157. Asia-Pacific Peptide API CDMO Services Consumption Value by Type (2021-2026) & (USD Million)
Table 158. Asia-Pacific Peptide API CDMO Services Consumption Value by Type (2027-2032) & (USD Million)
Table 159. Asia-Pacific Peptide API CDMO Services Consumption Value by Application (2021-2026) & (USD Million)
Table 160. Asia-Pacific Peptide API CDMO Services Consumption Value by Application (2027-2032) & (USD Million)
Table 161. Asia-Pacific Peptide API CDMO Services Consumption Value by Region (2021-2026) & (USD Million)
Table 162. Asia-Pacific Peptide API CDMO Services Consumption Value by Region (2027-2032) & (USD Million)
Table 163. South America Peptide API CDMO Services Consumption Value by Type (2021-2026) & (USD Million)
Table 164. South America Peptide API CDMO Services Consumption Value by Type (2027-2032) & (USD Million)
Table 165. South America Peptide API CDMO Services Consumption Value by Application (2021-2026) & (USD Million)
Table 166. South America Peptide API CDMO Services Consumption Value by Application (2027-2032) & (USD Million)
Table 167. South America Peptide API CDMO Services Consumption Value by Country (2021-2026) & (USD Million)
Table 168. South America Peptide API CDMO Services Consumption Value by Country (2027-2032) & (USD Million)
Table 169. Middle East & Africa Peptide API CDMO Services Consumption Value by Type (2021-2026) & (USD Million)
Table 170. Middle East & Africa Peptide API CDMO Services Consumption Value by Type (2027-2032) & (USD Million)
Table 171. Middle East & Africa Peptide API CDMO Services Consumption Value by Application (2021-2026) & (USD Million)
Table 172. Middle East & Africa Peptide API CDMO Services Consumption Value by Application (2027-2032) & (USD Million)
Table 173. Middle East & Africa Peptide API CDMO Services Consumption Value by Country (2021-2026) & (USD Million)
Table 174. Middle East & Africa Peptide API CDMO Services Consumption Value by Country (2027-2032) & (USD Million)
Table 175. Global Key Players of Peptide API CDMO Services Upstream (Raw Materials)
Table 176. Global Peptide API CDMO Services Typical Customers
Table 1. Global Peptide API CDMO Services Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Peptide API CDMO Services Consumption Value by Synthesis Technology, (USD Million), 2021 & 2025 & 2032
Table 3. Global Peptide API CDMO Services Consumption Value by Capacity Tier, (USD Million), 2021 & 2025 & 2032
Table 4. Global Peptide API CDMO Services Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Peptide API CDMO Services Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Peptide API CDMO Services Consumption Value by Region (2027-2032) & (USD Million)
Table 7. PolyPeptide (CH) Company Information, Head Office, and Major Competitors
Table 8. PolyPeptide (CH) Major Business
Table 9. PolyPeptide (CH) Peptide API CDMO Services Product and Solutions
Table 10. PolyPeptide (CH) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. PolyPeptide (CH) Recent Developments and Future Plans
Table 12. Bachem (CH) Company Information, Head Office, and Major Competitors
Table 13. Bachem (CH) Major Business
Table 14. Bachem (CH) Peptide API CDMO Services Product and Solutions
Table 15. Bachem (CH) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Bachem (CH) Recent Developments and Future Plans
Table 17. AmbioPharm (US) Company Information, Head Office, and Major Competitors
Table 18. AmbioPharm (US) Major Business
Table 19. AmbioPharm (US) Peptide API CDMO Services Product and Solutions
Table 20. AmbioPharm (US) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. CordenPharma (CH) Company Information, Head Office, and Major Competitors
Table 22. CordenPharma (CH) Major Business
Table 23. CordenPharma (CH) Peptide API CDMO Services Product and Solutions
Table 24. CordenPharma (CH) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. CordenPharma (CH) Recent Developments and Future Plans
Table 26. CPC Scientific (US) Company Information, Head Office, and Major Competitors
Table 27. CPC Scientific (US) Major Business
Table 28. CPC Scientific (US) Peptide API CDMO Services Product and Solutions
Table 29. CPC Scientific (US) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. CPC Scientific (US) Recent Developments and Future Plans
Table 31. Piramal Pharma Solutions (IN) Company Information, Head Office, and Major Competitors
Table 32. Piramal Pharma Solutions (IN) Major Business
Table 33. Piramal Pharma Solutions (IN) Peptide API CDMO Services Product and Solutions
Table 34. Piramal Pharma Solutions (IN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Piramal Pharma Solutions (IN) Recent Developments and Future Plans
Table 36. Almac Group (UK) Company Information, Head Office, and Major Competitors
Table 37. Almac Group (UK) Major Business
Table 38. Almac Group (UK) Peptide API CDMO Services Product and Solutions
Table 39. Almac Group (UK) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Almac Group (UK) Recent Developments and Future Plans
Table 41. Aspen API (ZA) Company Information, Head Office, and Major Competitors
Table 42. Aspen API (ZA) Major Business
Table 43. Aspen API (ZA) Peptide API CDMO Services Product and Solutions
Table 44. Aspen API (ZA) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Aspen API (ZA) Recent Developments and Future Plans
Table 46. Neuland Laboratories (IN) Company Information, Head Office, and Major Competitors
Table 47. Neuland Laboratories (IN) Major Business
Table 48. Neuland Laboratories (IN) Peptide API CDMO Services Product and Solutions
Table 49. Neuland Laboratories (IN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Neuland Laboratories (IN) Recent Developments and Future Plans
Table 51. USV (IN) Company Information, Head Office, and Major Competitors
Table 52. USV (IN) Major Business
Table 53. USV (IN) Peptide API CDMO Services Product and Solutions
Table 54. USV (IN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. USV (IN) Recent Developments and Future Plans
Table 56. Aurigene Pharmaceutical Services (IN) Company Information, Head Office, and Major Competitors
Table 57. Aurigene Pharmaceutical Services (IN) Major Business
Table 58. Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Product and Solutions
Table 59. Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Aurigene Pharmaceutical Services (IN) Recent Developments and Future Plans
Table 61. PeptiStar (JP) Company Information, Head Office, and Major Competitors
Table 62. PeptiStar (JP) Major Business
Table 63. PeptiStar (JP) Peptide API CDMO Services Product and Solutions
Table 64. PeptiStar (JP) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. PeptiStar (JP) Recent Developments and Future Plans
Table 66. BCN Peptides (ES) Company Information, Head Office, and Major Competitors
Table 67. BCN Peptides (ES) Major Business
Table 68. BCN Peptides (ES) Peptide API CDMO Services Product and Solutions
Table 69. BCN Peptides (ES) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. BCN Peptides (ES) Recent Developments and Future Plans
Table 71. Creative Peptides (US) Company Information, Head Office, and Major Competitors
Table 72. Creative Peptides (US) Major Business
Table 73. Creative Peptides (US) Peptide API CDMO Services Product and Solutions
Table 74. Creative Peptides (US) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. Creative Peptides (US) Recent Developments and Future Plans
Table 76. Space Peptides (CH) Company Information, Head Office, and Major Competitors
Table 77. Space Peptides (CH) Major Business
Table 78. Space Peptides (CH) Peptide API CDMO Services Product and Solutions
Table 79. Space Peptides (CH) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. Space Peptides (CH) Recent Developments and Future Plans
Table 81. Cambrex (US) Company Information, Head Office, and Major Competitors
Table 82. Cambrex (US) Major Business
Table 83. Cambrex (US) Peptide API CDMO Services Product and Solutions
Table 84. Cambrex (US) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Cambrex (US) Recent Developments and Future Plans
Table 86. Nippon Shokubai (JP) Company Information, Head Office, and Major Competitors
Table 87. Nippon Shokubai (JP) Major Business
Table 88. Nippon Shokubai (JP) Peptide API CDMO Services Product and Solutions
Table 89. Nippon Shokubai (JP) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 90. Nippon Shokubai (JP) Recent Developments and Future Plans
Table 91. ScinoPharm (TW) Company Information, Head Office, and Major Competitors
Table 92. ScinoPharm (TW) Major Business
Table 93. ScinoPharm (TW) Peptide API CDMO Services Product and Solutions
Table 94. ScinoPharm (TW) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 95. ScinoPharm (TW) Recent Developments and Future Plans
Table 96. ChengDu ShengNuo Biotec (CN) Company Information, Head Office, and Major Competitors
Table 97. ChengDu ShengNuo Biotec (CN) Major Business
Table 98. ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Product and Solutions
Table 99. ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 100. ChengDu ShengNuo Biotec (CN) Recent Developments and Future Plans
Table 101. WuXi TIDES (CN) Company Information, Head Office, and Major Competitors
Table 102. WuXi TIDES (CN) Major Business
Table 103. WuXi TIDES (CN) Peptide API CDMO Services Product and Solutions
Table 104. WuXi TIDES (CN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 105. WuXi TIDES (CN) Recent Developments and Future Plans
Table 106. Asymchem (CN) Company Information, Head Office, and Major Competitors
Table 107. Asymchem (CN) Major Business
Table 108. Asymchem (CN) Peptide API CDMO Services Product and Solutions
Table 109. Asymchem (CN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 110. Asymchem (CN) Recent Developments and Future Plans
Table 111. Medtide (CN) Company Information, Head Office, and Major Competitors
Table 112. Medtide (CN) Major Business
Table 113. Medtide (CN) Peptide API CDMO Services Product and Solutions
Table 114. Medtide (CN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Medtide (CN) Recent Developments and Future Plans
Table 116. Jiuzhou Pharma (CN) Company Information, Head Office, and Major Competitors
Table 117. Jiuzhou Pharma (CN) Major Business
Table 118. Jiuzhou Pharma (CN) Peptide API CDMO Services Product and Solutions
Table 119. Jiuzhou Pharma (CN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 120. Jiuzhou Pharma (CN) Recent Developments and Future Plans
Table 121. Hybio Pharmaceutical (CN) Company Information, Head Office, and Major Competitors
Table 122. Hybio Pharmaceutical (CN) Major Business
Table 123. Hybio Pharmaceutical (CN) Peptide API CDMO Services Product and Solutions
Table 124. Hybio Pharmaceutical (CN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 125. Hybio Pharmaceutical (CN) Recent Developments and Future Plans
Table 126. JYMed Peptide (CN) Company Information, Head Office, and Major Competitors
Table 127. JYMed Peptide (CN) Major Business
Table 128. JYMed Peptide (CN) Peptide API CDMO Services Product and Solutions
Table 129. JYMed Peptide (CN) Peptide API CDMO Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 130. JYMed Peptide (CN) Recent Developments and Future Plans
Table 131. Global Peptide API CDMO Services Revenue (USD Million) by Players (2021-2026)
Table 132. Global Peptide API CDMO Services Revenue Share by Players (2021-2026)
Table 133. Breakdown of Peptide API CDMO Services by Company Type (Tier 1, Tier 2, and Tier 3)
Table 134. Market Position of Players in Peptide API CDMO Services, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 135. Head Office of Key Peptide API CDMO Services Players
Table 136. Peptide API CDMO Services Market: Company Product Type Footprint
Table 137. Peptide API CDMO Services Market: Company Product Application Footprint
Table 138. Peptide API CDMO Services New Market Entrants and Barriers to Market Entry
Table 139. Peptide API CDMO Services Mergers, Acquisition, Agreements, and Collaborations
Table 140. Global Peptide API CDMO Services Consumption Value (USD Million) by Type (2021-2026)
Table 141. Global Peptide API CDMO Services Consumption Value Share by Type (2021-2026)
Table 142. Global Peptide API CDMO Services Consumption Value Forecast by Type (2027-2032)
Table 143. Global Peptide API CDMO Services Consumption Value by Application (2021-2026)
Table 144. Global Peptide API CDMO Services Consumption Value Forecast by Application (2027-2032)
Table 145. North America Peptide API CDMO Services Consumption Value by Type (2021-2026) & (USD Million)
Table 146. North America Peptide API CDMO Services Consumption Value by Type (2027-2032) & (USD Million)
Table 147. North America Peptide API CDMO Services Consumption Value by Application (2021-2026) & (USD Million)
Table 148. North America Peptide API CDMO Services Consumption Value by Application (2027-2032) & (USD Million)
Table 149. North America Peptide API CDMO Services Consumption Value by Country (2021-2026) & (USD Million)
Table 150. North America Peptide API CDMO Services Consumption Value by Country (2027-2032) & (USD Million)
Table 151. Europe Peptide API CDMO Services Consumption Value by Type (2021-2026) & (USD Million)
Table 152. Europe Peptide API CDMO Services Consumption Value by Type (2027-2032) & (USD Million)
Table 153. Europe Peptide API CDMO Services Consumption Value by Application (2021-2026) & (USD Million)
Table 154. Europe Peptide API CDMO Services Consumption Value by Application (2027-2032) & (USD Million)
Table 155. Europe Peptide API CDMO Services Consumption Value by Country (2021-2026) & (USD Million)
Table 156. Europe Peptide API CDMO Services Consumption Value by Country (2027-2032) & (USD Million)
Table 157. Asia-Pacific Peptide API CDMO Services Consumption Value by Type (2021-2026) & (USD Million)
Table 158. Asia-Pacific Peptide API CDMO Services Consumption Value by Type (2027-2032) & (USD Million)
Table 159. Asia-Pacific Peptide API CDMO Services Consumption Value by Application (2021-2026) & (USD Million)
Table 160. Asia-Pacific Peptide API CDMO Services Consumption Value by Application (2027-2032) & (USD Million)
Table 161. Asia-Pacific Peptide API CDMO Services Consumption Value by Region (2021-2026) & (USD Million)
Table 162. Asia-Pacific Peptide API CDMO Services Consumption Value by Region (2027-2032) & (USD Million)
Table 163. South America Peptide API CDMO Services Consumption Value by Type (2021-2026) & (USD Million)
Table 164. South America Peptide API CDMO Services Consumption Value by Type (2027-2032) & (USD Million)
Table 165. South America Peptide API CDMO Services Consumption Value by Application (2021-2026) & (USD Million)
Table 166. South America Peptide API CDMO Services Consumption Value by Application (2027-2032) & (USD Million)
Table 167. South America Peptide API CDMO Services Consumption Value by Country (2021-2026) & (USD Million)
Table 168. South America Peptide API CDMO Services Consumption Value by Country (2027-2032) & (USD Million)
Table 169. Middle East & Africa Peptide API CDMO Services Consumption Value by Type (2021-2026) & (USD Million)
Table 170. Middle East & Africa Peptide API CDMO Services Consumption Value by Type (2027-2032) & (USD Million)
Table 171. Middle East & Africa Peptide API CDMO Services Consumption Value by Application (2021-2026) & (USD Million)
Table 172. Middle East & Africa Peptide API CDMO Services Consumption Value by Application (2027-2032) & (USD Million)
Table 173. Middle East & Africa Peptide API CDMO Services Consumption Value by Country (2021-2026) & (USD Million)
Table 174. Middle East & Africa Peptide API CDMO Services Consumption Value by Country (2027-2032) & (USD Million)
Table 175. Global Key Players of Peptide API CDMO Services Upstream (Raw Materials)
Table 176. Global Peptide API CDMO Services Typical Customers
LIST OF FIGURES
Figure 1. Peptide API CDMO Services Picture
Figure 2. Global Peptide API CDMO Services Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Peptide API CDMO Services Consumption Value Market Share by Type in 2025
Figure 4. GMP Services
Figure 5. Non-GMP Services
Figure 6. Global Peptide API CDMO Services Consumption Value by Synthesis Technology, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Peptide API CDMO Services Consumption Value Market Share by Synthesis Technology in 2025
Figure 8. SPPS
Figure 9. LPPS
Figure 10. Hybrid Technology
Figure 11. Global Peptide API CDMO Services Consumption Value by Capacity Tier, (USD Million), 2021 & 2025 & 2032
Figure 12. Global Peptide API CDMO Services Consumption Value Market Share by Capacity Tier in 2025
Figure 13. Small-Scale (mg?g)
Figure 14. Medium-Scale (g?kg)
Figure 15. Large-Scale (kg?t)
Figure 16. Global Peptide API CDMO Services Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 17. Peptide API CDMO Services Consumption Value Market Share by Application in 2025
Figure 18. Commercial Picture
Figure 19. Scientific Research Picture
Figure 20. Other Picture
Figure 21. Global Peptide API CDMO Services Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 22. Global Peptide API CDMO Services Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 23. Global Market Peptide API CDMO Services Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 24. Global Peptide API CDMO Services Consumption Value Market Share by Region (2021-2032)
Figure 25. Global Peptide API CDMO Services Consumption Value Market Share by Region in 2025
Figure 26. North America Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 27. Europe Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 28. Asia-Pacific Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 29. South America Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 30. Middle East & Africa Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 31. Company Three Recent Developments and Future Plans
Figure 32. Global Peptide API CDMO Services Revenue Share by Players in 2025
Figure 33. Peptide API CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 34. Market Share of Peptide API CDMO Services by Player Revenue in 2025
Figure 35. Top 3 Peptide API CDMO Services Players Market Share in 2025
Figure 36. Top 6 Peptide API CDMO Services Players Market Share in 2025
Figure 37. Global Peptide API CDMO Services Consumption Value Share by Type (2021-2026)
Figure 38. Global Peptide API CDMO Services Market Share Forecast by Type (2027-2032)
Figure 39. Global Peptide API CDMO Services Consumption Value Share by Application (2021-2026)
Figure 40. Global Peptide API CDMO Services Market Share Forecast by Application (2027-2032)
Figure 41. North America Peptide API CDMO Services Consumption Value Market Share by Type (2021-2032)
Figure 42. North America Peptide API CDMO Services Consumption Value Market Share by Application (2021-2032)
Figure 43. North America Peptide API CDMO Services Consumption Value Market Share by Country (2021-2032)
Figure 44. United States Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 45. Canada Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 46. Mexico Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 47. Europe Peptide API CDMO Services Consumption Value Market Share by Type (2021-2032)
Figure 48. Europe Peptide API CDMO Services Consumption Value Market Share by Application (2021-2032)
Figure 49. Europe Peptide API CDMO Services Consumption Value Market Share by Country (2021-2032)
Figure 50. Germany Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 51. France Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 52. United Kingdom Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 53. Russia Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 54. Italy Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 55. Asia-Pacific Peptide API CDMO Services Consumption Value Market Share by Type (2021-2032)
Figure 56. Asia-Pacific Peptide API CDMO Services Consumption Value Market Share by Application (2021-2032)
Figure 57. Asia-Pacific Peptide API CDMO Services Consumption Value Market Share by Region (2021-2032)
Figure 58. China Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 59. Japan Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 60. South Korea Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 61. India Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 62. Southeast Asia Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 63. Australia Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 64. South America Peptide API CDMO Services Consumption Value Market Share by Type (2021-2032)
Figure 65. South America Peptide API CDMO Services Consumption Value Market Share by Application (2021-2032)
Figure 66. South America Peptide API CDMO Services Consumption Value Market Share by Country (2021-2032)
Figure 67. Brazil Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 68. Argentina Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 69. Middle East & Africa Peptide API CDMO Services Consumption Value Market Share by Type (2021-2032)
Figure 70. Middle East & Africa Peptide API CDMO Services Consumption Value Market Share by Application (2021-2032)
Figure 71. Middle East & Africa Peptide API CDMO Services Consumption Value Market Share by Country (2021-2032)
Figure 72. Turkey Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 73. Saudi Arabia Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 74. UAE Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 75. Peptide API CDMO Services Market Drivers
Figure 76. Peptide API CDMO Services Market Restraints
Figure 77. Peptide API CDMO Services Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Peptide API CDMO Services Industrial Chain
Figure 80. Methodology
Figure 81. Research Process and Data Source
Figure 1. Peptide API CDMO Services Picture
Figure 2. Global Peptide API CDMO Services Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Peptide API CDMO Services Consumption Value Market Share by Type in 2025
Figure 4. GMP Services
Figure 5. Non-GMP Services
Figure 6. Global Peptide API CDMO Services Consumption Value by Synthesis Technology, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Peptide API CDMO Services Consumption Value Market Share by Synthesis Technology in 2025
Figure 8. SPPS
Figure 9. LPPS
Figure 10. Hybrid Technology
Figure 11. Global Peptide API CDMO Services Consumption Value by Capacity Tier, (USD Million), 2021 & 2025 & 2032
Figure 12. Global Peptide API CDMO Services Consumption Value Market Share by Capacity Tier in 2025
Figure 13. Small-Scale (mg?g)
Figure 14. Medium-Scale (g?kg)
Figure 15. Large-Scale (kg?t)
Figure 16. Global Peptide API CDMO Services Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 17. Peptide API CDMO Services Consumption Value Market Share by Application in 2025
Figure 18. Commercial Picture
Figure 19. Scientific Research Picture
Figure 20. Other Picture
Figure 21. Global Peptide API CDMO Services Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 22. Global Peptide API CDMO Services Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 23. Global Market Peptide API CDMO Services Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 24. Global Peptide API CDMO Services Consumption Value Market Share by Region (2021-2032)
Figure 25. Global Peptide API CDMO Services Consumption Value Market Share by Region in 2025
Figure 26. North America Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 27. Europe Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 28. Asia-Pacific Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 29. South America Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 30. Middle East & Africa Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 31. Company Three Recent Developments and Future Plans
Figure 32. Global Peptide API CDMO Services Revenue Share by Players in 2025
Figure 33. Peptide API CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 34. Market Share of Peptide API CDMO Services by Player Revenue in 2025
Figure 35. Top 3 Peptide API CDMO Services Players Market Share in 2025
Figure 36. Top 6 Peptide API CDMO Services Players Market Share in 2025
Figure 37. Global Peptide API CDMO Services Consumption Value Share by Type (2021-2026)
Figure 38. Global Peptide API CDMO Services Market Share Forecast by Type (2027-2032)
Figure 39. Global Peptide API CDMO Services Consumption Value Share by Application (2021-2026)
Figure 40. Global Peptide API CDMO Services Market Share Forecast by Application (2027-2032)
Figure 41. North America Peptide API CDMO Services Consumption Value Market Share by Type (2021-2032)
Figure 42. North America Peptide API CDMO Services Consumption Value Market Share by Application (2021-2032)
Figure 43. North America Peptide API CDMO Services Consumption Value Market Share by Country (2021-2032)
Figure 44. United States Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 45. Canada Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 46. Mexico Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 47. Europe Peptide API CDMO Services Consumption Value Market Share by Type (2021-2032)
Figure 48. Europe Peptide API CDMO Services Consumption Value Market Share by Application (2021-2032)
Figure 49. Europe Peptide API CDMO Services Consumption Value Market Share by Country (2021-2032)
Figure 50. Germany Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 51. France Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 52. United Kingdom Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 53. Russia Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 54. Italy Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 55. Asia-Pacific Peptide API CDMO Services Consumption Value Market Share by Type (2021-2032)
Figure 56. Asia-Pacific Peptide API CDMO Services Consumption Value Market Share by Application (2021-2032)
Figure 57. Asia-Pacific Peptide API CDMO Services Consumption Value Market Share by Region (2021-2032)
Figure 58. China Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 59. Japan Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 60. South Korea Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 61. India Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 62. Southeast Asia Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 63. Australia Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 64. South America Peptide API CDMO Services Consumption Value Market Share by Type (2021-2032)
Figure 65. South America Peptide API CDMO Services Consumption Value Market Share by Application (2021-2032)
Figure 66. South America Peptide API CDMO Services Consumption Value Market Share by Country (2021-2032)
Figure 67. Brazil Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 68. Argentina Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 69. Middle East & Africa Peptide API CDMO Services Consumption Value Market Share by Type (2021-2032)
Figure 70. Middle East & Africa Peptide API CDMO Services Consumption Value Market Share by Application (2021-2032)
Figure 71. Middle East & Africa Peptide API CDMO Services Consumption Value Market Share by Country (2021-2032)
Figure 72. Turkey Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 73. Saudi Arabia Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 74. UAE Peptide API CDMO Services Consumption Value (2021-2032) & (USD Million)
Figure 75. Peptide API CDMO Services Market Drivers
Figure 76. Peptide API CDMO Services Market Restraints
Figure 77. Peptide API CDMO Services Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Peptide API CDMO Services Industrial Chain
Figure 80. Methodology
Figure 81. Research Process and Data Source
